| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Benefits Outweigh Risks Associated With Newborn Screening for Disorder ANN ARBOR, Mich -- February 1, 2010 -- Newborn screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) could lead to false positives -- adding stress to parents, costing money, and possibly subjecting a baby to unnecessary follow-up treatment and dietary restrictions. However, the benefits of diagnosing these children early and preventing the risk of mental retardation, disability or death outweigh the costs of a false positive, according to study published today in the February issue of the journal Pediatrics. “Published studies of expanded newborn screening in a United States setting have resulted in favourable cost-effective ratios for screening for this illness but did not include primary data for quality of life effects for a false positive screen,” said lead author Lisa Prosser, PhD, Division of General Pediatrics, University of Michigan Health System, Ann Arbor, Michigan. “Our results show that newborn screening remains cost-effective after accounting for the measured loss in quality of life associated with a false positive screen.” While MCADD patients are usually healthy, repeated episodes of metabolic crisis can cause permanent brain damage. This may result in learning problems and mental retardation. Researchers used a computer model that took into account costs of screening, including the initial screen test, parent time and medical costs of follow-up testing, treatment, and the quality of life implications of having dietary restrictions. They found that screening requires substantial investment of resources but in exchange for important health benefits. ”The cost-effectiveness of newborn screening for MCADD is comparable to cost-effectiveness for other childhood interventions, such as vaccinations,” said Dr. Prosser. “Newborn screening for MCADD remains cost-effective even when the loss in quality of life associated with false positives or dietary treatments are taken into account.”
SOURCE: University of Michigan Health System
|